Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging
Nenhuma Miniatura disponível
Data
2014-09-01
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Int Inst Anticancer Research
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
Background/Aim: Feline mammary carcinomas (FMCs) are characterized by poor prognosis and little progress has been made in extending patient survival. The aim of the study was to compare overall survival periods of FMCs submitted to different treatment protocols, including surgery and adjuvant chemotherapy. Materials and Methods: Analysis of conventional surgical excision alone or in association with adjuvant chemotherapy with carboplatin in sixteen cats diagnosed with stage III and grade II or III FMCs was performed. Results: Patients treated with surgery and chemotherapy presented a longer overall survival (OS) than those treated only with surgery, however, no statistical difference was observed when comparing both treatments (p=0.883). Conclusion: Therapeutic benefit of carboplatin remains invalidated for FMCs and further investigation regarding adjuvant therapies are warranted. Surgery remains as the gold treatment in FMCs.
Descrição
Palavras-chave
Idioma
Inglês
Como citar
In Vivo. Athens: Int Inst Anticancer Research, v. 28, n. 5, p. 863-866, 2014.